Company Dynamics Update
On April 7, 2025, Zhejiang Garden Biopharmaceutical Co., Ltd. (Garden Biopharma) announced significant progress in its key biotin and vitamin B6 (VB6) investment projects, expected to commence production in the second and third quarters of 2025. Meanwhile, Shandong Haineng Bioengineering Co., Ltd. (Haineng Bioengineering) held a product launch event on April 1, 2025, unveiling industry-leading standards for its 25-hydroxyvitamin D3 product.
Garden Biopharma’s Project Developments
Biotin Production Project
Garden Biopharma’s biotin project, with a total investment of USD 22.19 million (RMB 159.28 million), adopts advanced domestic design concepts, production equipment, and process technology. Key construction highlights include:
- Installation of reactors, centrifuges, three-in-one equipment, and fully automatic packaging machines
- New regenerative burner with 25,000 m3/h capacity
- Wastewater treatment system with a daily treatment capacity of 500 m3
Upon completion, the facility will achieve an annual production capacity of 200 tons (pure basis) of biotin, including 7,000 tonnes of biotin (2%) DP and 60 tonnes of food- and pharmaceutical-grade biotin.
Vitamin B6 (VB6) Production Project
The 5,000 t/a vitamin B6 project, located in Jinhua Economic and Technological Development Zone, involves a total investment of USD 46.73 million (RMB 335.39 million). After completion, the facility will produce:
- 3,000 t/a feed-grade vitamin B6
- 2,000 t/a food- and pharmaceutical-grade vitamin B6
- 7,200 t/a co-produced industrial potassium chloride
The construction encompasses four vitamin B6 workshops, a regional power plant, machine cabinets, and an extended tank area, enhancing the company’s capacity to meet growing domestic and international demand.
Company Background
Garden Biopharma specializes in R&D, production, and sales of vitamin D3 and related upstream and downstream products, including lanoline cholesterol, refined lanoline, 25-hydroxyvitamin D3, vitamin B3, and vitamin B5.
Haineng Bioengineering’s Launch of High-Standard 25-Hydroxyvitamin D3
Product Launch and Technical Achievements
On April 1, 2025, Haineng Bioengineering introduced its enhanced 25-hydroxyvitamin D3 product at the Haineng Innovation Centre in Rizhao, Shandong. This product sets a new industry benchmark, surpassing both domestic and international standards:
- Purity: ≥96%
- Individual Impurities: ≤0.5%
- Total Impurities: ≤2%
- 1,25-dihydroxyvitamin D3: Zero detection
In comparison, the current industry standards require ≥94% purity, ≤1% individual impurities, and ≤4% total impurities.
Technological Innovations
Haineng introduced micro-encapsulation coating technology, offering:
- Higher stability
- Better absorption
- Superior performance
- Easier application
Stability tests confirmed zero degradation within one year, significantly enhancing shelf life and application flexibility.
Company Background and Market Ambitions
Established in 2008, Haineng Bioengineering focuses on research and production of 25-hydroxyvitamin D3, liquid vitamin raw materials, and additive premixes. It is the second company in China to develop 25-hydroxyvitamin D3, breaking the long-standing monopoly previously held by U.S. companies. Haineng plans to capture 30% of the global market share within the next three to five years.
Industry Outlook
The ongoing expansion efforts of Garden Biopharma and Haineng Bioengineering reflect the growing demand for high-quality vitamin products, especially in feed, food, pharmaceutical, and nutraceutical industries. These developments are expected to strengthen China’s competitiveness in the global vitamin supply chain.
Accelerate Your Business with China Informatics
Partner with China Informatics for:
- Real-time Vitamin, pharmaceutical market analysis, price and project intelligence.
- Competitive intelligence on vitamin manufacturing projects across China.
- In-depth insights into company dynamics in China’s biopharmaceutical sector.
Our tailored solutions empower you to act faster and lead with confidence. Connect with China Informatics today.
